The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
Sign Up to like & getrecommendations! Published in 2017 at "Internal Medicine"
DOI: 10.2169/internalmedicine.56.7871
Abstract: Less than 5% of patients with polycythemia vera (PV) show JAK2 exon 12 mutations. Although PV patients with JAK2 exon 12 mutations are known to develop post-PV myelofibrosis (MF) as well as PV with JAK2V617F,… read more here.
Keywords: jak1 inhibitor; polycythemia vera; exon mutations; myelofibrosis ... See more keywords